LHRHa

Phase 3Small molecule

Johnson & Johnson

LHRHa is one of 98 small molecule programs targeting Cognitive impairment. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cognitive ImpairmentActive, not recruiting

Prostatic NeoplasmsActive, not recruiting

Prostate CancerActive, not recruiting

Cognitive ImpairmentPreclinical

Active, not recruiting

Prostatic NeoplasmsPhase 3

Active, not recruiting

Prostate CancerPhase 3

Active, not recruiting

Competition

Competitive Landscape

348 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Lutetium Lu-177 PNT2002

JJonsson Comprehensive Cancer Center

Phase 3

4 2

Triptorelin Embonate

Ipsen

Phase 3

3 3

LHRHa

Johnson & Johnson

Phase 3

2 4

Semaglutide Pen Injector

UUniversitaire Ziekenhuizen KU Leuven

Phase 3

1 5

Luteinizing Hormone Releasing Hormone

UUS Department of Veterans Affairs

Phase 3

2 6

SHR3680

JJiangsu HengRui Medicine Co., Ltd.

Phase 3

5 7

Rhpsma-7.3 (18f)

BBlue Earth Diagnostics

Phase 3

4 8

Lupron Depot

RRepros Therapeutics Inc.

Phase 3

2 9

HC-1119

HHinova Pharmaceuticals Inc.

Phase 3

2 10

Trexall

Jazz Pharmaceuticals

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2031

Phase 3Active, not recruiting

Prostatic Neoplasms

NCT04557059

Clinical

Trials by Indication[1]

Prostate Cancer2 trials

Neo-adjuvant Abiraterone + Luteinizing Hormone-Releasing Hormone (LHRH) Versus LHRH in Prostate Cancer

Completed·CCougar Biotechnology, Inc.·Phase 2·NCT01088529·66 enrolled

Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer

Active, not recruiting·UUniversity of Sydney·Phase 3·NCT02446444·802 enrolled

Cognitive impairment1 trial

Mild Cognitive Impairment in Men Following Androgen Deprivation

Withdrawn·IImperial College London·N/A·NCT01691976

Abiraterone Acetate1 trial

Abiraterone Acetate Plus LHRH Agonist and Abiraterone Acetate Plus LHRH Agonist and Enzalutamide

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01946165·69 enrolled

Prostatic Neoplasms1 trial

A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer, Assessed by PSMA-PET With an Observational Cohort

Active, not recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT04557059·691 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for LHRHa. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — LHRHa compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for LHRHa. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Johnson & Johnson company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Johnson & Johnson

LHRHa

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2031

Trials by Indication[1]

Prostate Cancer2 trials

Cognitive impairment1 trial

Abiraterone Acetate1 trial

Prostatic Neoplasms1 trial

References

Drug Info

Quick Facts

Related News